Download PDF
Semin Reprod Med 2021; 39(05/06): 207-219
DOI: 10.1055/s-0041-1735646
Review Article

The Use of Androgen Priming in Women with Reduced Ovarian Reserve Undergoing Assisted Reproductive Technology

Alison Richardson
1   Department of Reproductive Medicine and Surgery, University Hospitals of Leicester NHS Trust, Leicester Fertility Centre, Infirmary Square, Leicester, United Kingdom
,
Kanna Jayaprakasan 
2   Department of Reproductive Medicine and Surgery, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, United Kingdom
3   CARE Fertility Nottingham, Nottingham Business Park, Nottingham, United Kingdom
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Androgen priming with either dehydroepiandrosterone (DHEA) or testosterone has been suggested as an adjunct to improve in vitro fertilization (IVF) outcomes in women with diminished ovarian reserve (DOR). Numerous studies have investigated the effects of both DHEA and testosterone on IVF outcome. The results were inconsistent, and the quality of most studies is substandard. Meta-analyses have consistently reported that DHEA does appear to significantly improve IVF outcome in women with predicted or proven poor ovarian response (POR), but these have included some normal responders and/or nonrandomized studies. Our meta-analyses including randomized controlled trials (RCTs) incorporating only women with DOR or POR suggest that DHEA confers no benefit. While meta-analyses of RCTs on the use of testosterone in women with DOR or POR showed an improved IVF outcome, most studies included are of low quality with high risk of bias. When analysis of data from studies of only low-risk bias was performed, such a benefit with testosterone was not observed. Although recruitment may well be a challenge, a large, well-designed RCT is, however, still warranted to investigate whether or not androgen priming with either DHEA or testosterone should be recommended as an adjuvant treatment for women with DOR or POR undergoing IVF.

Keywords

DHEA - testosterone - ovarian response - poor responders - IVF - clinical pregnancy


Publication History

Article published online:
09 September 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Wallace WH, Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 2004; 19 (07) 1612-1617
    CrossrefPubMedGoogle Scholar
  • 2 Baker TG. A quantitative and cytological study of germ cells in human ovaries. Proc R Soc Lond B Biol Sci 1963; 158: 417-433
    CrossrefPubMedGoogle Scholar
  • 3 Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages. Acta Anat (Basel) 1952; 14 (1-2): 108-123
    CrossrefPubMedGoogle Scholar
  • 4 Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65 (06) 1231-1237
    CrossrefPubMedGoogle Scholar
  • 5 Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod 1996; 11 (07) 1484-1486
    CrossrefPubMedGoogle Scholar
  • 6 Baird DT, Collins J, Egozcue J. et al; ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update 2005; 11 (03) 261-276
    CrossrefPubMedGoogle Scholar
  • 7 Padilla SL, Garcia JE. Effect of maternal age and number of in vitro fertilization procedures on pregnancy outcome. Fertil Steril 1989; 52 (02) 270-273
    CrossrefPubMedGoogle Scholar
  • 8 Ubaldi FM, Cimadomo D, Vaiarelli A. et al. Advanced maternal age in IVF: still a challenge? The present and the future of its treatment. Front Endocrinol (Lausanne) 2019; 10: 94
    CrossrefPubMedGoogle Scholar
  • 9 Yeung T, Chai J, Li R, Lee V, Ho PC, Ng E. A double-blind randomised controlled trial on the effect of dehydroepiandrosterone on ovarian reserve markers, ovarian response and number of oocytes in anticipated normal ovarian responders. BJOG 2016; 123 (07) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 10 Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2000; 73 (04) 667-676
    CrossrefPubMedGoogle Scholar
  • 11 Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2010; (01) CD004379
    PubMedGoogle Scholar
  • 12 Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel?. Fertil Steril 2011; 96 (05) 1058-61.e7
    CrossrefPubMedGoogle Scholar
  • 13 NICE. Fertility problems: assessment and treatment. [CG156], 2017. Accessed August 20, 2021 at: https://www.nice.org.uk/guidance/cg156
    Google Scholar
  • 14 Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26 (07) 1616-1624
    CrossrefPubMedGoogle Scholar
  • 15 Løssl K, Freiesleben NC, Wissing ML. et al. Biological and clinical rationale for androgen priming in ovarian stimulation. Front Endocrinol (Lausanne) 2020; 11: 627
    CrossrefPubMedGoogle Scholar
  • 16 Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 2010; 24 (07) 1393-1403
    CrossrefPubMedGoogle Scholar
  • 17 Walters KA, Simanainen U, Handelsman DJ. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 2010; 16 (05) 543-558
    CrossrefPubMedGoogle Scholar
  • 18 Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 101 (12) 2622-2629
    CrossrefPubMedGoogle Scholar
  • 19 Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999; 84 (08) 2951-2956
    CrossrefPubMedGoogle Scholar
  • 20 Weil SJ, Vendola K, Zhou J. et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998; 83 (07) 2479-2485
    CrossrefPubMedGoogle Scholar
  • 21 Rice S, Ojha K, Whitehead S, Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J Clin Endocrinol Metab 2007; 92 (03) 1034-1040
    CrossrefPubMedGoogle Scholar
  • 22 Jeppesen JV, Kristensen SG, Nielsen ME. et al. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol Metab 2012; 97 (08) E1524-E1531
    CrossrefPubMedGoogle Scholar
  • 23 Saunders PT, Millar MR, Williams K. et al. Differential expression of estrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. Biol Reprod 2000; 63 (04) 1098-1105
    CrossrefPubMedGoogle Scholar
  • 24 Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996; 17 (02) 121-155
    CrossrefPubMedGoogle Scholar
  • 25 Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003; 21 (05) 346-355
    CrossrefPubMedGoogle Scholar
  • 26 Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78 (06) 1360-1367
    CrossrefPubMedGoogle Scholar
  • 27 Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000; 15 (10) 2129-2132
    CrossrefPubMedGoogle Scholar
  • 28 Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006; 21 (11) 2845-2849
    CrossrefPubMedGoogle Scholar
  • 29 Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007; 24 (12) 629-634
    CrossrefPubMedGoogle Scholar
  • 30 Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011; 9: 67
    CrossrefPubMedGoogle Scholar
  • 31 Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol 2009; 7: 108
    CrossrefPubMedGoogle Scholar
  • 32 Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015; (11) CD009749
    PubMedGoogle Scholar
  • 33 Nardo LG, El-Toukhy T, Stewart J, Balen AH, Potdar N. British Fertility Society Policy and Practice Committee. British Fertility Society Policy and Practice Committee: adjuvants in IVF: evidence for good clinical practice. Hum Fertil (Camb) 2015; 18 (01) 2-15
    CrossrefPubMedGoogle Scholar
  • 34 Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and thecal cells. J Clin Endocrinol Metab 1968; 28 (03) 355-358
    CrossrefPubMedGoogle Scholar
  • 35 Horie K, Takakura K, Fujiwara H, Suginami H, Liao S, Mori T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Hum Reprod 1992; 7 (02) 184-190
    CrossrefPubMedGoogle Scholar
  • 36 Garcia-Velasco JA, Moreno L, Pacheco A. et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005; 84 (01) 82-87
    CrossrefPubMedGoogle Scholar
  • 37 Nielsen ME, Rasmussen IA, Kristensen SG. et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011; 17 (01) 63-70
    CrossrefPubMedGoogle Scholar
  • 38 Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999; 61 (02) 353-357
    CrossrefPubMedGoogle Scholar
  • 39 Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril 2001; 76 (02) 241-248
    CrossrefPubMedGoogle Scholar
  • 40 Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil Steril 2009; 91 (02) 644-646
    CrossrefPubMedGoogle Scholar
  • 41 Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr Opin Obstet Gynecol 2009; 21 (04) 306-308
    CrossrefPubMedGoogle Scholar
  • 42 Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?. Reprod Biol Endocrinol 2011; 9: 116
    CrossrefPubMedGoogle Scholar
  • 43 Ménézo Y, Dale B, Cohen M. DNA damage and repair in human oocytes and embryos: a review. Zygote 2010; 18 (04) 357-365
    CrossrefPubMedGoogle Scholar
  • 44 Pitteloud N, Mootha VK, Dwyer AA. et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28 (07) 1636-1642
    CrossrefPubMedGoogle Scholar
  • 45 Triantafyllidou O, Sigalos G, Vlahos N. Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders. Hum Fertil (Camb) 2017; 20 (02) 80-87
    CrossrefPubMedGoogle Scholar
  • 46 Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecol Endocrinol 2013; 29 (10) 940-943
    CrossrefPubMedGoogle Scholar
  • 47 Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol 2010; 8: 140
    CrossrefPubMedGoogle Scholar
  • 48 Sönmezer M, Ozmen B, Cil AP. et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod Biomed Online 2009; 19 (04) 508-513
    CrossrefPubMedGoogle Scholar
  • 49 Jirge PR, Chougule SM, Gavali VG, Bhomkar DA. Impact of dehydroepiandrosterone on clinical outcome in poor responders: a pilot study in women undergoing in vitro fertilization, using bologna criteria. J Hum Reprod Sci 2014; 7 (03) 175-180
    CrossrefPubMedGoogle Scholar
  • 50 Singh N, Zangmo R, Kumar S. et al. A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve. Gynecol Endocrinol 2013; 29 (11) 989-992
    CrossrefPubMedGoogle Scholar
  • 51 Zangmo R, Singh N, Kumar S, Vanamail P, Tiwari A. Role of dehydroepiandrosterone in improving oocyte and embryo quality in IVF cycles. Reprod Biomed Online 2014; 28 (06) 743-747
    CrossrefPubMedGoogle Scholar
  • 52 Vlahos N, Papalouka M, Triantafyllidou O. et al. Dehydroepiandrosterone administration before IVF in poor responders: a prospective cohort study. Reprod Biomed Online 2015; 30 (02) 191-196
    CrossrefPubMedGoogle Scholar
  • 53 Weissman A, Horowitz E, Ravhon A, Golan A, Levran D. Dehydroepiandrosterone supplementation increases baseline follicular phase progesterone levels. Gynecol Endocrinol 2011; 27 (12) 1014-1017
    CrossrefPubMedGoogle Scholar
  • 54 Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010; 25 (10) 2496-2500
    CrossrefPubMedGoogle Scholar
  • 55 Artini PG, Simi G, Ruggiero M. et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol Endocrinol 2012; 28 (09) 669-673
    CrossrefPubMedGoogle Scholar
  • 56 Moawad M, Shaeer M. Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study. Middle East Fertil Soc J 2012; 17 (04) 268-274
    CrossrefPubMedGoogle Scholar
  • 57 Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?. Eur J Obstet Gynecol Reprod Biol 2014; 173: 63-65
    CrossrefPubMedGoogle Scholar
  • 58 Yeung TW, Chai J, Li RH, Lee VC, Ho PC, Ng EH. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 2014; 102 (01) 108-115.e1
    CrossrefPubMedGoogle Scholar
  • 59 Zhang HH, Xu PY, Wu J. et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J Ovarian Res 2014; 7: 93
    CrossrefPubMedGoogle Scholar
  • 60 Kotb MM, Hassan AM, AwadAllah AM. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2016; 200: 11-15
    CrossrefPubMedGoogle Scholar
  • 61 Narkwichean A, Maalouf W, Baumgarten M. et al. Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial. Eur J Obstet Gynecol Reprod Biol 2017; 218: 39-48
    CrossrefPubMedGoogle Scholar
  • 62 Tartagni M, Cicinelli MV, Baldini D. et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reprod Biol Endocrinol 2015; 13: 18
    CrossrefPubMedGoogle Scholar
  • 63 Tartagni M, De Pergola G, Damiani GR. et al. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecol 2015; 67 (01) 7-12
    PubMedGoogle Scholar
  • 64 Yeung TW, Li RH, Lee VC, Ho PC, Ng EH. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J Clin Endocrinol Metab 2013; 98 (01) 380-388
    CrossrefPubMedGoogle Scholar
  • 65 Divita AE, Kanzepolsky LS, Notrica JA. et al. Does dehidroepiandrosterone sulfate (DHEAS) co- treatment improve art outcome? A prospective, randomized, double-blind placebo-controlled trial. Fertil Steril 2003; 80: S111-S112
    CrossrefPubMedGoogle Scholar
  • 66 Evans JA. A randomised, double blinded, placebo controlled, single centre trial comparing dehydroepiandrosterone (DHEA) and placebo in the treatment of women with resistant ovaries prior to in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI). BJOG 2013; 93: 225
    PubMedGoogle Scholar
  • 67 Jindal A, Singh R. A prospective randomised controlled study on the role of dehydroepiandrosterone (DHEA) on improving ovarian response in known poor responders in previous failed IVF-ICSI cycles. Hum Reprod 2014; 29: i14
    PubMedGoogle Scholar
  • 68 Li J, Yuan H, Chen Y, Wu H, Wu H, Li L. A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. Int J Gynaecol Obstet 2015; 131 (03) 240-245
    CrossrefPubMedGoogle Scholar
  • 69 Schwarze JE, Canales J, Crosby J, Ortega-Hrepich C, Villa S, Pommer R. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: a systematic review and meta-analysis. JBRA Assist Reprod 2018; 22 (04) 369-374
    PubMedGoogle Scholar
  • 70 Liu Y, Hu L, Fan L, Wang F. Efficacy of dehydroepiandrosterone (DHEA) supplementation for in vitro fertilization and embryo transfer cycles: a systematic review and meta-analysis. Gynecol Endocrinol 2018; 34 (03) 178-183
    CrossrefPubMedGoogle Scholar
  • 71 Xu L, Hu C, Liu Q, Li Y. The effect of dehydroepiandrosterone (DHEA) supplementation on IVF or ICSI: a meta-analysis of randomized controlled trials. Geburtshilfe Frauenheilkd 2019; 79 (07) 705-712
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Zhang Y, Zhang C, Shu J. et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update 2020; 26 (02) 247-263
    CrossrefPubMedGoogle Scholar
  • 73 Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP, Hugues JN. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique–a prospective, randomized, double-blind study. Hum Reprod 2006; 21 (05) 1204-1211
    CrossrefPubMedGoogle Scholar
  • 74 Fábregues F, Peñarrubia J, Creus M. et al. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod 2009; 24 (02) 349-359
    CrossrefPubMedGoogle Scholar
  • 75 Kim CH, Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011; 95 (02) 679-683
    CrossrefPubMedGoogle Scholar
  • 76 Kim CH, Ahn JW, Moon JW, Kim SH, Chae HD, Kang BM. Ovarian features after 2 weeks, 3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF outcomes in poor responders. Dev Reprod 2014; 18 (03) 145-152
    CrossrefPubMedGoogle Scholar
  • 77 Bosdou JK, Venetis CA, Dafopoulos K. et al. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Hum Reprod 2016; 31 (05) 977-985
    CrossrefPubMedGoogle Scholar
  • 78 Saharkhiz N, Zademodares S, Salehpour S, Hosseini S, Nazari L, Tehrani HG. The effect of testosterone gel on fertility outcomes in women with a poor response in in vitro fertilization cycles: a pilot randomized clinical trial. J Res Med Sci 2018; 23: 3
    CrossrefPubMedGoogle Scholar
  • 79 Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007; 13 (03) 239-248
    CrossrefPubMedGoogle Scholar
  • 80 van Vollenhoven RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2002; 3 (01) 23-31
    CrossrefPubMedGoogle Scholar
  • 81 Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005; (04) CD004509
    PubMedGoogle Scholar
  • 82 Dean CE. Prasterone (DHEA) and mania. Ann Pharmacother 2000; 34 (12) 1419-1422
    CrossrefPubMedGoogle Scholar
  • 83 Labrie F, Luu-The V, Labrie C. et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24 (02) 152-182
    CrossrefPubMedGoogle Scholar
  • 84 Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002; 17 (10) 2573-2579
    CrossrefPubMedGoogle Scholar
  • 85 Bosch E, Broer S, Griesinger G. et al; ESHRE Guideline Group on Ovarian Stimulation. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020; 2020 (04) a067
    CrossrefPubMedGoogle Scholar
  • 86 Zhang H, Chu Y, Zhou P. et al. Dehydroepiandrosterone plus climen supplementation shows better effects than dehydroepiandrosterone alone on infertility patients with diminished ovarian reserve of low-FSH level undergoing in-vitro fertilization cycles: a randomized controlled trial. Reprod Biol Endocrinol 2016; 14: 9
    CrossrefPubMedGoogle Scholar
  • 87 Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsbøll S, Andersen AN. Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial. Hum Reprod 2008; 23 (08) 1820-1829
    CrossrefPubMedGoogle Scholar
  • 88 Durnerin CI, Erb K, Fleming R. et al; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008; 23 (02) 421-426
    CrossrefPubMedGoogle Scholar
  • 89 Bercaire L, Nogueira SM, Lima PC. et al. ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation. JBRA Assist Reprod 2018; 22 (01) 52-55
    PubMedGoogle Scholar
  • 90 Thuesen LL, Loft A, Egeberg AN, Smitz J, Petersen JH, Andersen AN. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod 2012; 27 (10) 3074-3084
    CrossrefPubMedGoogle Scholar
  • 91 Smitz J, Andersen AN, Devroey P, Arce JC. MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod 2007; 22 (03) 676-687
    CrossrefPubMedGoogle Scholar
  • 92 Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev 2017; 11: CD008528
    PubMedGoogle Scholar